Semih Eren
Research Subjects
Semih Eren has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Ali Nazmi Çalık
UHS, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Cardiology Department, Istanbul, Turkey
5 shared publications - Ahmet Çağdaş Yumurtaş
Department of Cardiology, Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training Hospital, Istanbul, Turkey
4 shared publications - Levent Pay
Department of Cardiology Istanbul Haseki Training and Research Hospital Istanbul Turkey
4 shared publications - Mert İlker Hayıroğlu
Health Sciences University, Turkey
4 shared publications - Ozan Tezen
Department of Cardiology, Bayrampasa State Hospital, Istanbul, Turkey
4 shared publications - Sukru Akyuz
Department of Cardiology, Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (38) , e50738
Early clinical and hemodynamic outcomes of SAVR, Ozaki neocuspidization, and TAVI
Aortic stenosis is a common valvular heart disease associated with substantial morbidity and mortality if left untreated. Surgical aortic valve replacement (SAVR), transcatheter aortic valve implantation (TAVI), and autologous pericardial aortic valve reconstruction (Ozaki procedure) represent alternative interventional strategies, but direct real-world comparisons remain limited. This study evaluated early clinical and 6-month hemodynamic outcomes following these 3 treatment approaches. This retrospective single-center observational study included 153 consecutive patients with severe aortic stenosis treated between December 2020 and March 2022 (SAVR, n = 67; Ozaki, n = 31; TAVI, n = 55). Early mortality was the primary clinical outcome, and 6-month mean transvalvular gradient was the primary echocardiographic outcome. Other clinical and echocardiographic outcomes were considered secondary or exploratory. Multivariable regression, analysis of covariance, and separate pairwise propensity-score matching models were used to account for baseline differences. Propensity scores were estimated using age, sex, EuroSCORE II, chronic kidney disease, and coronary artery disease. TAVI patients were older and had higher operative risk. No statistically significant differences were detected among the groups in early mortality, stroke, or postoperative dialysis. Permanent pacemaker implantation was more frequent after TAVI, while prolonged intensive care unit stay also differed among treatment groups. At 6 months, the Ozaki group showed favorable hemodynamic parameters, including lower mean transvalvular gradients and maximum transvalvular velocity. However, 6-month echocardiographic follow-up was incomplete, and these findings should be considered exploratory given the small Ozaki cohort, baseline differences, and observational study design. SAVR, Ozaki neocuspidization, and TAVI showed distinct early clinical and hemodynamic profiles in this real-world observational cohort. No statistically significant differences were detected in several major early clinical outcomes, although the study was not sufficiently powered to establish equivalent safety or exclude clinically meaningful differences. The favorable short-term hemodynamic findings observed with the Ozaki procedure should be considered hypothesis-generating. Larger prospective studies with longer follow-up are needed to further evaluate comparative clinical outcomes, hemodynamic performance, and durability.
- 18 September 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (38) , e50738
Open AccessEarly clinical and hemodynamic outcomes of SAVR, Ozaki neocuspidization, and TAVI
Aortic stenosis is a common valvular heart disease associated with substantial morbidity and mortality if left untreated. Surgical aortic valve replacement (SAVR), transcatheter aortic valve implantation (TAVI), and autologous pericardial aortic valve reconstruction (Ozaki procedure) represent alternative interventional strategies, but direct real-world comparisons remain limited. This study evaluated early clinical and 6-month hemodynamic outcomes following these 3 treatment approaches. This retrospective single-center observational study included 153 consecutive patients with severe aortic stenosis treated between December 2020 and March 2022 (SAVR, n = 67; Ozaki, n = 31; TAVI, n = 55). Early mortality was the primary clinical outcome, and 6-month mean transvalvular gradient was the primary echocardiographic outcome. Other clinical and echocardiographic outcomes were considered secondary or exploratory. Multivariable regression, analysis of covariance, and separate pairwise propensity-score matching models were used to account for baseline differences. Propensity scores were estimated using age, sex, EuroSCORE II, chronic kidney disease, and coronary artery disease. TAVI patients were older and had higher operative risk. No statistically significant differences were detected among the groups in early mortality, stroke, or postoperative dialysis. Permanent pacemaker implantation was more frequent after TAVI, while prolonged intensive care unit stay also differed among treatment groups. At 6 months, the Ozaki group showed favorable hemodynamic parameters, including lower mean transvalvular gradients and maximum transvalvular velocity. However, 6-month echocardiographic follow-up was incomplete, and these findings should be considered exploratory given the small Ozaki cohort, baseline differences, and observational study design. SAVR, Ozaki neocuspidization, and TAVI showed distinct early clinical and hemodynamic profiles in this real-world observational cohort. No statistically significant differences were detected in several major early clinical outcomes, although the study was not sufficiently powered to establish equivalent safety or exclude clinically meaningful differences. The favorable short-term hemodynamic findings observed with the Ozaki procedure should be considered hypothesis-generating. Larger prospective studies with longer follow-up are needed to further evaluate comparative clinical outcomes, hemodynamic performance, and durability.
- 16 June 2026
- Published by SAGE Publications in Angiology
Predictive Value of the Uric Acid-to-Albumin Ratio for In-Hospital Mortality in Acute Pulmonary Embolism
Pulmonary embolism (PE) remains a major cause of cardiovascular mortality, and early identification of high-risk patients is essential. The uric acid-to-albumin ratio (UAR) has emerged as a marker reflecting systemic inflammation. This study aimed to evaluate the prognostic value of UAR for in-hospital mortality in patients with acute PE. This single-center, retrospective study included 1052 consecutive patients diagnosed with acute PE. Clinical characteristics, laboratory parameters, echocardiographic findings, and pulmonary imaging results were obtained from hospital records. Multivariable logistic regression analyses were performed to identify independent predictors of in-hospital mortality. The discriminative performance of UAR was assessed using receiver operating characteristic (ROC) curve analysis. Overall, 70 patients (6.7%) died during hospitalization. Non-survivors had significantly higher UAR values compared with survivors (2.33 vs 1.57, P < .001). In multivariable analysis, UAR C-Reactive Protein, and Pulmonary artery severity index (PESI) score independently predicted in-hospital mortality. UAR demonstrated acceptable discriminative ability (Area under the curve .728; 95% CI: .649-.807; P < .001), with an optimal cut-off of 2.12. The combined use of UAR and PESI demonstrated a modest improvement in predictive performance. UAR is an independent predictor of in-hospital mortality in patients with acute PE. Its combination with the PESI score may provide incremental value for early risk stratification.
- 16 June 2026
- Published by SAGE Publications in Angiology
Predictive Value of the Uric Acid-to-Albumin Ratio for In-Hospital Mortality in Acute Pulmonary Embolism
Pulmonary embolism (PE) remains a major cause of cardiovascular mortality, and early identification of high-risk patients is essential. The uric acid-to-albumin ratio (UAR) has emerged as a marker reflecting systemic inflammation. This study aimed to evaluate the prognostic value of UAR for in-hospital mortality in patients with acute PE. This single-center, retrospective study included 1052 consecutive patients diagnosed with acute PE. Clinical characteristics, laboratory parameters, echocardiographic findings, and pulmonary imaging results were obtained from hospital records. Multivariable logistic regression analyses were performed to identify independent predictors of in-hospital mortality. The discriminative performance of UAR was assessed using receiver operating characteristic (ROC) curve analysis. Overall, 70 patients (6.7%) died during hospitalization. Non-survivors had significantly higher UAR values compared with survivors (2.33 vs 1.57, P < .001). In multivariable analysis, UAR C-Reactive Protein, and Pulmonary artery severity index (PESI) score independently predicted in-hospital mortality. UAR demonstrated acceptable discriminative ability (Area under the curve .728; 95% CI: .649-.807; P < .001), with an optimal cut-off of 2.12. The combined use of UAR and PESI demonstrated a modest improvement in predictive performance. UAR is an independent predictor of in-hospital mortality in patients with acute PE. Its combination with the PESI score may provide incremental value for early risk stratification.
- 20 April 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (4) , 452-460
Impact of bifurcation angles on clinical outcomes of TAP technique in STEMI
Coronary bifurcation lesions remain one of the frequently encountered and technically challenging scenarios in percutaneous coronary interventions (PCI), accounting for approximately 15-20% of all ...
- 20 April 2026
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 81 (4) , 452-460
Impact of bifurcation angles on clinical outcomes of TAP technique in STEMI
Coronary bifurcation lesions remain one of the frequently encountered and technically challenging scenarios in percutaneous coronary interventions (PCI), accounting for approximately 15-20% of all ...
- Open Access
- 20 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1403
The Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Objectives: Our aim was to investigate whether admission advanced lung cancer inflammation index (ALI) values have a prognostic role on one-year major adverse cardiovascular and cerebrovascular events (MACCEs) in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). Methods: Our study consisted of 1173 consecutive patients aged 61.9 ± 12.5 years. The study population was divided into two groups according to the occurrence of MACCEs. BMI (body mass index), serum albumin levels and NLR (neutrophil to lymphocyte ratio) of patients were collected from hospital records, and ALI was calculated based on the following formula: BMI × serum albumin/NLR. We also calculated neutrophil to lymphocyte ratio (NLR), C-reactive protein/albumin ratio (CAR) and uric acid to albumin ratio (UAR) and investigated the association of these inflammation-based biomarkers with one-year MACCEs. Results: During the 12-month follow-up period, 158 (13.5%) patients had MACCEs, 55 (4.7%) of whom had all-cause mortality, 96 (8.2%) had nonfatal MI and 7 (0.6%) had nonfatal stroke. Patients with MACCEs had significantly lower ALI (p < 0.001), and also ALI (area under the curve [AUC] = 0.658, p < 0.001) had better discriminatory power and predictive accuracy in determining one-year MACCEs compared to albumin (AUC = 0.594, p < 0.001), NLR (AUC = 0.631, p < 0.001), CAR (AUC = 0.595, p < 0.001) and UAR (AUC = 0.577, p = 0.001) in the ROC analysis. Individuals with an ALI value lower than 43.9 were at greater risk of developing MACCEs (p < 0.001) due to the Delong test. Conclusions: Determining the level of ALI may have the potential to improve risk prognostication in NSTEMI patients undergoing revascularization therapy.
- 20 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1403
Open AccessThe Prognostic Value of the Advanced Lung Cancer Inflammation Index for Major Cardiovascular and Cerebrovascular Events in Patients with Non-ST Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
Objectives: Our aim was to investigate whether admission advanced lung cancer inflammation index (ALI) values have a prognostic role on one-year major adverse cardiovascular and cerebrovascular events (MACCEs) in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). Methods: Our study consisted of 1173 consecutive patients aged 61.9 ± 12.5 years. The study population was divided into two groups according to the occurrence of MACCEs. BMI (body mass index), serum albumin levels and NLR (neutrophil to lymphocyte ratio) of patients were collected from hospital records, and ALI was calculated based on the following formula: BMI × serum albumin/NLR. We also calculated neutrophil to lymphocyte ratio (NLR), C-reactive protein/albumin ratio (CAR) and uric acid to albumin ratio (UAR) and investigated the association of these inflammation-based biomarkers with one-year MACCEs. Results: During the 12-month follow-up period, 158 (13.5%) patients had MACCEs, 55 (4.7%) of whom had all-cause mortality, 96 (8.2%) had nonfatal MI and 7 (0.6%) had nonfatal stroke. Patients with MACCEs had significantly lower ALI (p < 0.001), and also ALI (area under the curve [AUC] = 0.658, p < 0.001) had better discriminatory power and predictive accuracy in determining one-year MACCEs compared to albumin (AUC = 0.594, p < 0.001), NLR (AUC = 0.631, p < 0.001), CAR (AUC = 0.595, p < 0.001) and UAR (AUC = 0.577, p = 0.001) in the ROC analysis. Individuals with an ALI value lower than 43.9 were at greater risk of developing MACCEs (p < 0.001) due to the Delong test. Conclusions: Determining the level of ALI may have the potential to improve risk prognostication in NSTEMI patients undergoing revascularization therapy.
- Open Access
- 27 September 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5) , e20230791
Valor Prognóstico da Escore PRECİSE DAPT em Resultados de Curto e Longo Prazo em Pacientes MINOCA com Síndrome Coronariana Aguda
Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas [...] Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas
- 27 September 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5) , e20230791
Open AccessValor Prognóstico da Escore PRECİSE DAPT em Resultados de Curto e Longo Prazo em Pacientes MINOCA com Síndrome Coronariana Aguda
Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas [...] Introdução Pacientes com infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) representam 6% a 14% de todos aqueles com infarto agudo do miocárdio (IAM).– O diagnóstico de MINOCA depende da presença de IAM clínico e da ausência de doença arterial coronariana obstrutiva (DAC). Na verdade, MINOCA é inicialmente considerado um diagnóstico válido durante a angiografia até que outras possíveis causas de elevação da troponina sejam excluídas. As causas subjacentes podem ser condições coronarianas ou não coronarianas, incluindo doenças cardíacas
- Open Access
- 7 May 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5)
Prognostic Value of PRECİSE DAPT Score on Short- and Long-Term Outcomes in MINOCA Patients with Acute Coronary Syndrome
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) constitutes a significant subset of acute myocardial infarctions (AMI) with uncertain prognostic markers. Early risk assessment is crucial to identify MINOCA patients at risk of adverse outcomes. Objectives: This study aimed to evaluate the predictive capacity of the PRECISE-DAPT score in assessing short- and long-term prognoses in MINOCA patients presenting with ST-segment elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Methods: Among 741 MINOCA patients, the PRECISE-DAPT score was computed to analyze its association with inhospital and follow-up major adverse cardiovascular events (MACE). Parameters showing significance in MACE (+) groups underwent statistical analysis: univariate logistic regression for in-hospital events and univariate Cox regression for follow-up events. For statistical significance, a predefined level of α = 0.05 was adopted. Parameters demonstrating significance proceeded to multiple logistic regression for in-hospital events and multivariate Cox regression for followup events. Results: In-hospital MACE occurred in 4.1% of patients, while 58% experienced follow-up MACE. Hemoglobin levels and the PRECISE-DAPT Score were identified as independent parameters for in-hospital MACE. Furthermore, ejection fraction (EF%) and the PRECISE-DAPT Score emerged as independent predictors of follow-up MACE. Conclusions: The study revealed that a higher PRECISE-DAPT score was significantly associated with increased risks of both in-hospital and long-term major adverse cardiovascular events in MINOCA patients presenting with acute coronary syndrome (ACS), underscoring the score’s potential in risk stratification for this patient cohort.
- 7 May 2024
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 121 (5)
Open AccessPrognostic Value of PRECİSE DAPT Score on Short- and Long-Term Outcomes in MINOCA Patients with Acute Coronary Syndrome
Background: Myocardial infarction with non-obstructive coronary arteries (MINOCA) constitutes a significant subset of acute myocardial infarctions (AMI) with uncertain prognostic markers. Early risk assessment is crucial to identify MINOCA patients at risk of adverse outcomes. Objectives: This study aimed to evaluate the predictive capacity of the PRECISE-DAPT score in assessing short- and long-term prognoses in MINOCA patients presenting with ST-segment elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Methods: Among 741 MINOCA patients, the PRECISE-DAPT score was computed to analyze its association with inhospital and follow-up major adverse cardiovascular events (MACE). Parameters showing significance in MACE (+) groups underwent statistical analysis: univariate logistic regression for in-hospital events and univariate Cox regression for follow-up events. For statistical significance, a predefined level of α = 0.05 was adopted. Parameters demonstrating significance proceeded to multiple logistic regression for in-hospital events and multivariate Cox regression for followup events. Results: In-hospital MACE occurred in 4.1% of patients, while 58% experienced follow-up MACE. Hemoglobin levels and the PRECISE-DAPT Score were identified as independent parameters for in-hospital MACE. Furthermore, ejection fraction (EF%) and the PRECISE-DAPT Score emerged as independent predictors of follow-up MACE. Conclusions: The study revealed that a higher PRECISE-DAPT score was significantly associated with increased risks of both in-hospital and long-term major adverse cardiovascular events in MINOCA patients presenting with acute coronary syndrome (ACS), underscoring the score’s potential in risk stratification for this patient cohort.
- 17 April 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (8) , 363-371
Prognostic value of serum albumin in heart failure patients with cardiac resynchronization therapy
Aim: There is a lack of data about the association between admission serum albumin levels and long-term mortality in heart failure (HF) patients with cardiac resynchronization therapy defibrillators (CRT-D). We aim to investigate this connection in HF patients with CRT-D. Methods: The study population consisted of 477 HF patients with CRT-D. The cohort was divided into three groups according to albumin values, and the relationship between these groups and long-term mortality were evaluated. Results: Long-term all-cause mortality (HR: 3.32, 95% CI: 2.12-6.84), appropriate (HR: 4.44, 95% CI: 2.44-8.06) and inappropriate (HR: 2.95, 95% CI: 1.88-6.02) shocks were higher in the low albumin group. Conclusion: Low albumin levels are associated with the long-term mortality and appropriate shock treatment in HF patients with CRT-D.
- 17 April 2024
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 18 (8) , 363-371
Prognostic value of serum albumin in heart failure patients with cardiac resynchronization therapy
Aim: There is a lack of data about the association between admission serum albumin levels and long-term mortality in heart failure (HF) patients with cardiac resynchronization therapy defibrillators (CRT-D). We aim to investigate this connection in HF patients with CRT-D. Methods: The study population consisted of 477 HF patients with CRT-D. The cohort was divided into three groups according to albumin values, and the relationship between these groups and long-term mortality were evaluated. Results: Long-term all-cause mortality (HR: 3.32, 95% CI: 2.12-6.84), appropriate (HR: 4.44, 95% CI: 2.44-8.06) and inappropriate (HR: 2.95, 95% CI: 1.88-6.02) shocks were higher in the low albumin group. Conclusion: Low albumin levels are associated with the long-term mortality and appropriate shock treatment in HF patients with CRT-D.
- 19 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1186-1197
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long‐term cardiovascular events
Introduction: Drug‐eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by improving event‐free survival compared to older stent designs. However, early‐generation DES with polymer matrixes have raised concerns regarding late stent thrombosis due to delayed vascular healing. To address these issues, biologically bioabsorbable polymer drug‐eluting stents (BP‐DES) and polymer‐free drug‐eluting stents (PF‐DES) have been developed.Aim: The aim of the present study is to evaluate and compare the long‐term effects of different stent platforms in patients with acute coronary syndrome (ACS) undergoing PCI.Material and Methods: We conducted a retrospective, observational study involving 1192 ACS patients who underwent urgent PCI. Patients were treated with thin‐ strut DP‐DES, ultra‐thin strut BP‐DES, or thin‐strut PF‐DES. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CITLR) at 12 months and 4 years.Results: The baseline demographics and clinical characteristics of patients in the three stent subgroups were similar. No significant differences were observed in target lesion failure (TLF), cardiac mortality, TVMI, and stent thrombosis (ST) rates among the three subgroups at both 12 months and 4 years. However, beyond the first year, the rate of CITLR was significantly lower in the ultra‐thin strut BP‐DES subgroup compared to thin‐strut DP‐DES, suggesting potential long‐term advantages of ultra‐thin strut BP‐DES. Additionally, both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrated lower ST rates after the first year compared to thin‐strut DP‐DES.Conclusion: Our study highlights the potential advantages of ultra‐thin strut BP‐DES in reducing CITLR rates in the long term, and both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrate lower rates of ST beyond the first year compared to thin‐strut DP‐DES. However, no significant differences were observed in overall TLF, cardiac mortality and TVMI rates among the three stent subgroups at both 12 months and 4 years.
- 19 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1186-1197
The relation of polymer structure of stent used in patients with acute coronary syndrome revascularized by stent implantation with long‐term cardiovascular events
Introduction: Drug‐eluting stents (DES) have revolutionized percutaneous coronary intervention (PCI) by improving event‐free survival compared to older stent designs. However, early‐generation DES with polymer matrixes have raised concerns regarding late stent thrombosis due to delayed vascular healing. To address these issues, biologically bioabsorbable polymer drug‐eluting stents (BP‐DES) and polymer‐free drug‐eluting stents (PF‐DES) have been developed.Aim: The aim of the present study is to evaluate and compare the long‐term effects of different stent platforms in patients with acute coronary syndrome (ACS) undergoing PCI.Material and Methods: We conducted a retrospective, observational study involving 1192 ACS patients who underwent urgent PCI. Patients were treated with thin‐ strut DP‐DES, ultra‐thin strut BP‐DES, or thin‐strut PF‐DES. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction (TVMI), and clinically driven target lesion revascularization (CITLR) at 12 months and 4 years.Results: The baseline demographics and clinical characteristics of patients in the three stent subgroups were similar. No significant differences were observed in target lesion failure (TLF), cardiac mortality, TVMI, and stent thrombosis (ST) rates among the three subgroups at both 12 months and 4 years. However, beyond the first year, the rate of CITLR was significantly lower in the ultra‐thin strut BP‐DES subgroup compared to thin‐strut DP‐DES, suggesting potential long‐term advantages of ultra‐thin strut BP‐DES. Additionally, both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrated lower ST rates after the first year compared to thin‐strut DP‐DES.Conclusion: Our study highlights the potential advantages of ultra‐thin strut BP‐DES in reducing CITLR rates in the long term, and both ultra‐thin strut BP‐DES and thin‐strut PF‐DES demonstrate lower rates of ST beyond the first year compared to thin‐strut DP‐DES. However, no significant differences were observed in overall TLF, cardiac mortality and TVMI rates among the three stent subgroups at both 12 months and 4 years.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (12) , e20230703
Effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
Heart failure patients with reduced ejection fraction are at high risk for ventricular arrhythmias and sudden cardiac death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, provides heart rate reduction in sinus rhythm and angina control in chronic coronary syndromes.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (12) , e20230703
Open AccessEffect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction
Heart failure patients with reduced ejection fraction are at high risk for ventricular arrhythmias and sudden cardiac death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, provides heart rate reduction in sinus rhythm and angina control in chronic coronary syndromes.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (9) , 621-631
Efficiency of MVP ECG Risk Score for Prediction of Long-Term Atrial Fibrillation in Patients With ICD for Heart Failure With Reduced Ejection Fraction
Korean Circulation Journal 대한심장학회지 순환기 Pay L, et al. Korean Circ J. 2023 Jun;53:e49. https://doi.org/10.4070/kcj.2022.0353
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (9) , 621-631
Open AccessEfficiency of MVP ECG Risk Score for Prediction of Long-Term Atrial Fibrillation in Patients With ICD for Heart Failure With Reduced Ejection Fraction
Korean Circulation Journal 대한심장학회지 순환기 Pay L, et al. Korean Circ J. 2023 Jun;53:e49. https://doi.org/10.4070/kcj.2022.0353